Medical technology company iRhythm Technologies NASDAQ:IRTCbeat Wall Street’s revenue expectations in Q2 CY2026, with sales up 20.1% year on year to $224.2 million. The company expects the full year’s revenue to be around $885 million, close to analysts’ estimates. Its non-GAAP profit of $0.58 per share was significantly above analysts’ consensus estimates.
iRhythm (IRTC) Q2 CY2026 Highlights:
- Revenue: $224.2 million vs analyst estimates of $219.2 million (20.1% year-on-year growth, 2.3% beat)
- Adjusted EPS: $0.58 vs analyst estimates of $0 (significant beat)
- Adjusted EBITDA: $43.3 million vs analyst estimates of $26.13 million (19.3% margin, 65.7% beat)
- The company slightly lifted its revenue guidance for the full year to $885 million at the midpoint from $880 million
- Operating Margin: -1.1%, up from -10% in the same quarter last year
- Market Capitalization: $4.09 billion
“Our second quarter results reflect strong execution across the business, with broad-based growth, meaningful margin expansion, and continued progress against our strategic priorities,” said Quentin Blackford, President and Chief Executive Officer of iRhythm.
Company Overview
Pioneering the shift from bulky, short-term heart monitors to sleek, wire-free patches, iRhythm Technologies NASDAQ:IRTC provides wearable cardiac monitoring devices and AI-powered analysis services that help physicians detect and diagnose heart rhythm disorders.
Revenue Growth
Examining a company’s long-term performance can provide clues about its quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. Thankfully, iRhythm’s 21.9% annualized revenue growth over the last five years was excellent. Its growth beat the average healthcare company and shows its offerings resonate with customers, a helpful starting point for our analysis.
We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. iRhythm’s annualized revenue growth of 24% over the last two years is above its five-year trend, suggesting its demand was strong and recently accelerated.
This quarter, iRhythm reported robust year-on-year revenue growth of 20.1%, and its $224.2 million of revenue topped Wall Street estimates by 2.3%.
Looking ahead, sell-side analysts expect revenue to grow 14.7% over the next 12 months, a deceleration versus the last two years. Still, this projection is healthy and indicates the market is baking in success for its products and services.
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same.
Adjusted Operating Margin
Adjusted operating margin is an important measure of profitability as it shows the portion of revenue left after accounting for all core expenses — everything from the cost of goods sold to advertising and wages. It’s also useful for comparing profitability across companies because it excludes non-recurring expenses, interest on debt, and taxes.
Although iRhythm was profitable this quarter from an operational perspective, it’s generally struggled over a longer time period. Its expensive cost structure has contributed to an average adjusted operating margin of negative 13.2% over the last five years. Unprofitable healthcare companies require extra attention because they could get caught swimming naked when the tide goes out.
On the plus side, iRhythm’s adjusted operating margin rose by 28.9 percentage points over the last five years, as its sales growth gave it operating leverage. Zooming in on its more recent performance, we can see the company’s trajectory is intact as its margin has also increased by 21.7 percentage points on a two-year basis. These data points are very encouraging and show momentum is on its side.
This quarter, iRhythm generated an adjusted operating margin profit margin of 7.8%, up 14.4 percentage points year on year. This increase was a welcome development and shows it was more efficient.
Earnings Per Share
We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable.
iRhythm’s full-year EPS flipped from negative to positive over the last five years. This is a good sign and shows it’s at an inflection point.
In Q2, iRhythm reported adjusted EPS of $0.58, up from negative $0.32 in the same quarter last year. This print easily cleared analysts’ estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects iRhythm’s full-year EPS to grow 21.3% from $0.46 to $0.56.
Key Takeaways from iRhythm’s Q2 Results
It was good to see iRhythm beat analysts’ EPS expectations this quarter. We were also happy its revenue outperformed Wall Street’s estimates. Overall, we think this was a solid quarter with some key areas of upside. The stock traded up 3.1% to $132 immediately following the results.
iRhythm had an encouraging quarter, but one earnings result doesn’t necessarily make the stock a buy. Let’s see if this is a good investment. What happened in the latest quarter matters, but not as much as longer-term business quality and valuation, when deciding whether to invest in this stock. .